Berliner Boersenzeitung - 'Finally we can protect women': Japan's HPV vaccine battle

EUR -
AED 4.104397
AFN 76.945413
ALL 99.231189
AMD 432.617988
ANG 2.010719
AOA 1036.724537
ARS 1075.538681
AUD 1.641361
AWG 2.011389
AZN 1.904081
BAM 1.955429
BBD 2.252673
BDT 133.324726
BGN 1.955529
BHD 0.42062
BIF 3234.286875
BMD 1.117438
BND 1.441627
BOB 7.709539
BRL 6.055052
BSD 1.115688
BTN 93.249023
BWP 14.748204
BYN 3.651208
BYR 21901.788071
BZD 2.248874
CAD 1.517649
CDF 3208.165381
CHF 0.949812
CLF 0.037689
CLP 1039.944272
CNY 7.880067
CNH 7.870123
COP 4641.820049
CRC 578.89026
CUC 1.117438
CUP 29.612111
CVE 110.244101
CZK 25.088056
DJF 198.672338
DKK 7.466767
DOP 66.967305
DZD 147.657009
EGP 54.142736
ERN 16.761573
ETB 129.466357
FJD 2.459262
FKP 0.850995
GBP 0.83876
GEL 3.051043
GGP 0.850995
GHS 17.539675
GIP 0.850995
GMD 76.548818
GNF 9639.172699
GTQ 8.624365
GYD 233.395755
HKD 8.706352
HNL 27.675753
HRK 7.597474
HTG 147.212093
HUF 393.517458
IDR 16941.25656
ILS 4.226056
IMP 0.850995
INR 93.284241
IQD 1461.522939
IRR 47035.770303
ISK 152.262556
JEP 0.850995
JMD 175.286771
JOD 0.791709
JPY 160.715589
KES 143.922717
KGS 94.13132
KHR 4531.14103
KMF 493.181764
KPW 1005.693717
KRW 1488.975611
KWD 0.340897
KYD 0.929724
KZT 534.908597
LAK 24636.329683
LBP 99909.860054
LKR 340.395471
LRD 223.1377
LSL 19.586187
LTL 3.299505
LVL 0.675928
LYD 5.297996
MAD 10.818149
MDL 19.468309
MGA 5046.04342
MKD 61.598323
MMK 3629.395577
MNT 3797.054841
MOP 8.955702
MRU 44.337595
MUR 51.268486
MVR 17.164273
MWK 1934.433289
MXN 21.694843
MYR 4.698871
MZN 71.348848
NAD 19.586187
NGN 1831.984424
NIO 41.062216
NOK 11.714943
NPR 149.198716
NZD 1.791197
OMR 0.429669
PAB 1.115688
PEN 4.181807
PGK 4.367172
PHP 62.188829
PKR 309.994034
PLN 4.274593
PYG 8704.349913
QAR 4.067529
RON 4.972492
RSD 117.064808
RUB 103.380402
RWF 1504.014883
SAR 4.193134
SBD 9.282489
SCR 14.59602
SDG 672.143165
SEK 11.365691
SGD 1.442952
SHP 0.850995
SLE 25.530448
SLL 23432.113894
SOS 637.579134
SRD 33.752262
STD 23128.713955
SVC 9.762149
SYP 2807.596846
SZL 19.593286
THB 36.793929
TJS 11.859752
TMT 3.911034
TND 3.380559
TOP 2.617156
TRY 38.124201
TTD 7.588561
TWD 35.736832
TZS 3045.822602
UAH 46.114158
UGX 4133.216465
USD 1.117438
UYU 46.101261
UZS 14197.308611
VEF 4047978.463464
VES 41.096875
VND 27494.566096
VUV 132.664504
WST 3.125992
XAF 655.832674
XAG 0.035881
XAU 0.000426
XCD 3.019933
XDR 0.826843
XOF 655.832674
XPF 119.331742
YER 279.722751
ZAR 19.477909
ZMK 10058.288435
ZMW 29.537401
ZWL 359.814634
  • RBGPF

    58.8300

    58.83

    +100%

  • CMSD

    0.0100

    25.02

    +0.04%

  • JRI

    -0.0800

    13.32

    -0.6%

  • BCC

    -7.1900

    137.5

    -5.23%

  • NGG

    0.7200

    69.55

    +1.04%

  • SCS

    -0.3900

    12.92

    -3.02%

  • GSK

    -0.8200

    40.8

    -2.01%

  • RELX

    -0.1400

    47.99

    -0.29%

  • RIO

    -1.6100

    63.57

    -2.53%

  • RYCEF

    0.0200

    6.97

    +0.29%

  • BCE

    -0.1500

    35.04

    -0.43%

  • AZN

    -0.5200

    78.38

    -0.66%

  • CMSC

    0.0300

    25.15

    +0.12%

  • VOD

    -0.0500

    10.01

    -0.5%

  • BTI

    -0.1300

    37.44

    -0.35%

  • BP

    -0.1200

    32.64

    -0.37%

'Finally we can protect women': Japan's HPV vaccine battle
'Finally we can protect women': Japan's HPV vaccine battle

'Finally we can protect women': Japan's HPV vaccine battle

Thousands of lives could be saved as Japan begins to actively promote the HPV vaccine -- which can prevent cervical cancer -- after a decade of misinformation and weak policy left inoculation rates dismally low, advocates say.

Text size:

The percentage of teenage girls getting the human papillomavirus (HPV) vaccine has been close to zero since the country's 2013 decision not to promote the jab as panic erupted over alleged side effects.

But from Friday, authorities will actively recommend and share information about the vaccine, which is free for girls aged 12-16 in Japan and has been found safe in extensive trials.

"Finally we can protect the lives of young women," ruling party politician Junko Mihara, a former vice health minister and cervical cancer survivor, told AFP.

Even then, "we will lose so many lives because of the past eight years," she said.

Nearly always caused by sexually-transmitted HPV, cervical cancer is the fourth most common type of the disease in women globally.

In Japan, around 10,000 women develop cervical cancer each year, and it causes nearly 3,000 deaths.

Yet the World Health Organization regards the disease as "preventable and curable" and has outlined a strategy to eliminate it, which includes having 90 percent of girls inoculated by the age of 15 by 2030.

More than 100 countries have started using the vaccine, including Britain, where cervical cancer cases have already plummeted among women who received the jab, according to a recent study in The Lancet medical journal.

- Misinformation -

When Japan added the HPV vaccine to its national programme of routine inoculations in April 2013, initial uptake from the target group, girls aged 12-16, was around 70 percent.

But the government stopped actively promoting the jab just two months later, as sensationalist reports of alleged harmful side effects spread fear among the public.

It was still available for free, but without official endorsement, take-up soon dropped to less than one percent.

"The health ministry placed more emphasis on public opinion than scientific evidence," said Kanako Inaba, a gynecologist who runs an organisation providing information on the HPV vaccine.

This week's policy shift follows years of campaigning by medics and advocates like Mihara, a former actress who went into politics in 2010 to advocate for the new HPV vaccine.

But she struggled to battle misinformation, with media reports failing to make clear the difference between health problems that occurred after vaccination, and side effects directly linked to the jab.

Families gave emotional accounts on TV claiming the HPV vaccine had left their daughters unable to walk, and pro-vaccine campaigners like Mihara found themselves the target of angry abuse.

"People came to my office, and faxes kept coming," she recalled.

While there have been concerns over Japanese vaccine hesitancy in the past, the success of the country's Covid-19 vaccine drive -- with 80 percent of the population double-jabbed -- shows how influential government policy can be, according to Inaba.

"The government should have also taken a firm stance on the HPV vaccine, by providing evidence," like they did with the Covid vaccine, the doctor said.

Now, as more HPV shots are given, healthcare workers should "understand that girls might be anxious" about side-effects, and "provide information in an empathetic way," she added.

- 'Not afraid' -

A 2020 study in The Lancet predicted that Japan's "HPV vaccine crisis" could result in an additional 5,000 cervical cancer deaths among girls born between 1994 and 2007, compared to if uptake had remained at 70 percent.

The health ministry is trying to minimise the damage by offering free HPV vaccines to women who missed the shot over the past nine years, when they were of target age.

University student Utako Kawakami, 20, wishes she had been vaccinated before becoming sexually active.

Her mother was wary about giving her the shot as a teen due to media reports, although she has now changed her mind.

Kawakami got her second HPV vaccine dose last year, however, and told AFP she "wasn't afraid".

"I made my decision based on data," said the 20-year-old, who now posts information about the vaccine on social media for younger followers.

The vaccine's promotion still faces some opposition, notably from women who say they suffer pain, fatigue or other conditions after being inoculated.

Several lawsuits have been filed against the government and drugmakers since 2016 over alleged side effects, but no verdicts have yet been made.

For lawmaker Mihara, who had her uterus removed after developing cervical cancer, accurate information is key to boosting the vaccination rate.

"I don't want younger people to go through what I went through," she said.

(A.Lehmann--BBZ)